Perspective Therapeutics
CATX
Market cap $155M

2.30 USD

+0.03

1.32%

At close Mar 27, 4:00 PM EDT

After hours

2.38

+0.08

3.48%

1 day

1.32%

5 days

-5.74%

1 month

-11.88%

3 months

-27.90%

6 months

-81.70%

Year to date

-30.51%

1 year

-80.83%

5 years

-58.33%

10 years

-86.14%

About: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Employees: 119

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 7,390 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

58% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 31

50% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 24

6% more funds holding

Funds holding: 127 [Q3] → 134 (+7) [Q4]

2.96% less ownership

Funds ownership: 72.86% [Q3] → 69.9% (-2.96%) [Q4]

37% less call options, than puts

Call options by funds: $331K | Put options by funds: $527K

50% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]

77% less capital invested

Capital invested by funds: $655M [Q3] → $151M (-$505M) [Q4]

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

335%

upside

Avg. target

$12.75

454%

upside

High target

$15

552%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

RBC Capital Gregory Renza 35% 1-year accuracy 26 / 75 met price target	552%upside $15	Outperform Maintained	27 Mar 2025
Wedbush David Nierengarten 38% 1-year accuracy 45 / 119 met price target	378%upside $11	Outperform Reiterated	27 Mar 2025
HC Wainwright & Co. Robert Burns 22% 1-year accuracy 38 / 169 met price target	335%upside $10	Buy Reiterated	19 Mar 2025
Scotiabank Louise Chen 35% 1-year accuracy 48 / 139 met price target	552%upside $15	Sector Outperform Initiated	7 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about CATX published over the past 30 days

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

SEATTLE, March 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2024.

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced today that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of [212Pb]VMT01, a targeted alpha-particle therapy (TAT), in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans.

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

H.C. Wainwright & Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. CATX, a clinical-stage biotechnology company advancing “targeted radiotherapy agents” for cancer treatment.

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

Perspective Therapeutics to Present at Upcoming March Investor Conferences

SEATTLE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Perspective Therapeutics to Present at Upcoming March Investor Conferences

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

SEATTLE, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its full year 2024 financial results and provide a business update on Wednesday, March 26, 2025 after the market closes. The press release will be available in the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Perspective Therapeutics to Participate in Upcoming February Investor Conferences

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Updated interim results with an additional 10 weeks of follow-up on the nine patients in Cohorts 1 (2.5 mCi) and Cohort 2 (5.0 mCi) of the ongoing Phase 1/2a study support continuation of dose-finding for [ 212 Pb]VMT-α-NET [ 212 Pb]VMT-α-NET continued to have a favorable safety profile, with no dose-limiting toxicities observed at the two doses tested Three of seven patients in Cohort 2 experienced investigator-assessed objective responses as defined by RECIST v1.1. First responses for two patients occurred after end of treatment period and are subject to confirmation, in addition to the previously reported patient with confirmed response who remains in response The five other patients in Cohorts 1 and 2 who previously experienced stable disease remain in stable disease SEATTLE, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET that are being presented as a poster presentation at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) taking place January 23-25, 2025 in San Francisco, CA.

Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

SEATTLE, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the appointment of Juan Graham as the Company's Chief Financial Officer (CFO), effective as of January 6, 2025. In connection with the transition, Jonathan Hunt will no longer serve as CFO but will continue serving as the Company's Chief Accounting Officer (CAO).

Perspective Therapeutics Appoints Juan Graham, MBA as Chief Financial Officer

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Perspective Therapeutics' radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company's theranostics approach that delivers radiation directly to tumors. This can potentially minimize healthy tissue damage, and it has already had promising early results in neuroendocrine tumors. Currently, CATX's main candidates are VMT01 for melanoma and VMT-α-NET for neuroendocrine tumors. They're both in Phase 1/2 trials, and VMT01 has Fast Track Designation.

Bullish On Perspective Therapeutics: Early Successes And Large Oncology TAM

Perspective Therapeutics: Definitely Not Looking Overvalued Now

Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to continue research for years, despite current market skepticism and a significant drop in valuation. Alpha emitter PRRT offers a potentially safer alternative to beta emitters, but faces challenges in manufacturing, handling, and market uptake.

Perspective Therapeutics: Definitely Not Looking Overvalued Now

See News Rankings

Charts implemented using Lightweight Charts™